Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Beam Therapeutics Inc.”

10 pharma patents match "Beam Therapeutics Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 10
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 10 pharmaceutical patents matching "Beam Therapeutics Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

10 results for “Beam Therapeutics Inc.” · 30,257 patents in full index Clear search

  1. US 12296053

    Nanomaterials comprising triols

    Beam Therapeutics Inc. · Granted May 13, 2025 · Expires May 8, 2045

    granted
  2. US 12268753

    Nanomaterials comprising a biodegradable feature

    Beam Therapeutics Inc. · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  3. US 12133884

    Methods of substituting pathogenic amino acids using programmable base editor systems

    Beam Therapeutics Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  4. US 12059477

    Nanomaterials

    Beam Therapeutics Inc. · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted
  5. US 12016908

    Compositions and methods for treating hemoglobinopathies

    Beam Therapeutics Inc. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  6. US 11795443

    Uses of adenosine base editors

    Beam Therapeutics Inc. · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted
  7. US 11752202

    Compositions and methods for treating hemoglobinopathies

    Beam Therapeutics Inc. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted
  8. US 11344609

    Compositions and methods for treating hemoglobinopathies

    Beam Therapeutics Inc. · Granted May 31, 2022 · Expires May 26, 2042

    granted
  9. US 11155803

    Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequence

    Beam Therapeutics Inc. · Granted Oct 26, 2021 · Expires Oct 21, 2041

    granted
  10. US 11142760

    Compositions and methods for treating hemoglobinopathies

    Beam Therapeutics Inc. · Granted Oct 12, 2021 · Expires Oct 7, 2041

    granted